drugset / Trial / NCT02445352

Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia

NCT02445352

Phase 3 Completed 379 enrolled Alvogen Korea
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of DP-R207 in patients with primary hypercholesterolemia.

Timeline

Start
2014-07
Primary completion
2015-01
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg
Comparator Rosuvastatin Small molecule 5 mg
Comparator Rosuvastatin Small molecule 10 mg
Comparator Rosuvastatin Small molecule 20 mg

Indications